Universal Cancer Peptide-based Vaccination in Metastatic NSCLC
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
UCPVAx is a therapeutic vaccine based on the telomerase-derived UCP designed to induce strong
TH1 CD4 T cell responses in cancer patients.
Three doses of UCPVax (0,25 mg, 0,5 mg and 1 mg) will be tested in this phase I/II study by
using Continuous Reassessment Method (CRML) dose escalation design model.
The phase I is a dose escalation study designed to evaluate safety of use of UCPVax and to
estimate its Maximum Tolerated Dose (MTD).
The phase II is a dose deescalation designed to evaluate the immunogenicity of UCPVax
according to the dose level.